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ABSTRACT 
 
Background: Pseudoephedrine (PSE), a sympathomimetic drug, commonly 
used in nasal decongestants, is currently banned in sport by the World Anti-
Doping Agency (WADA), as its stimulant activity is claimed to enhance 
performance. This meta-analysis described the effects of PSE on factors 
relating to sport performance. 
Methods: All included studies were randomised placebo-controlled trials and 
were conducted in a double blind crossover fashion. All participants (males and 
females) were deemed to be healthy. For the primary analysis, standardised 
mean difference effect sizes (ES) were calculated for heart rate (HR), time trial 
(TT) performance, rating of perceived exertion (RPE), blood  (GLU), and blood 
lactate (BL). 
Results: Across all parameters, effects were trivial with the exception of HR, 
which showed a small positive increase in favour of PSE ingestion (ES = 0.43; 
95% confidence interval: -0.01 to 0.88). However, subgroup analyses revealed 
important trends. Effect sizes for HR (increase) and TT (quicker) were larger in 
well-trained (VO2 max (maximal oxygen consumption) ≥65 ml/kg/min) and 
younger (<28 years) participants, for shorter (<25 mins) bouts of exercise and 
when PSE was administered less than 90 minutes prior to performance. There 
was evidence of a dose-response effect for TT and HR with larger doses (>170 
mg) resulting in small (ES = -0.24) and moderate (ES = 0.85) effect sizes 
respectively for these variables. 
Conclusion: We conclude, however, that the performance benefit of 
pseudoephedrine is marginal and likely to be less than that obtained from 
permitted stimulants such as caffeine. 
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Key points: 
 Pseudoephedrine use exerts an effect on heart rate but there is no effect 
on time trial performance, perceived effort or biochemical markers (blood 
glucose and blood lactate). 
 Effects could be more apparent in just those athletes of most concern to 
anti-doping agencies: younger and well-trained athletes. 
 Any performance benefit of pseudoephedrine is marginal and certainly 
less than that obtained through permitted stimulants such as caffeine 
 
Background 
Pseudoephedrine (PSE) is a sympathomimetic amine derived from the plant genus 
Ephedra, most commonly used at therapeutic levels (60 mg) to relieve nasal 
congestion. The principal mechanism of action of PSE relies on the indirect stimulation 
of peripheral α1-adrenergic receptors, although it also has some ability to stimulate 
cardiac  receptors. This causes vasoconstriction at the level of the nasal mucosa, 
therefore reducing the blood flow to the nasal cavity and decreasing inflammation [1]. 
Despite being the optimal drug for this condition in many countries, access to PSE is 
restricted as it is a precursor material for the illegal manufacture of amphetamine. 
Instead, the less effective phenylephrine is favoured [2].  
 
Due to its similarity in structure with ephedrine and other central nervous system 
stimulants, there has been speculation that PSE may also exert ergogenic effects. 
Previously reviewed by Trinh et al. [3], these effects include increased systolic and 
diastolic blood pressure and heart rate, vasoconstriction in the cutaneous vessels, 
vasodilation in the skeletal muscle and breakdown of glycogen in the liver and muscle. 
Increased glycogenolysis could lead to increased glucose supply when it is limiting in 
exercise, whereas the proposed inotropic and chronotropic effects on the heart could 
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raise cardiac output, promoting blood flow to working muscle and potentially improving 
performance [4,5]. Regardless of the theoretical advantages of PSE, the results of 
studies to document its efficacy as an ergogenic agent are equivocal. Many studies 
have found little, or no, ergogenic effect [6–12], although some researchers reported 
larger-than-therapeutic doses to be effective in enhancing performance [13–15].  
  
This inconsistency in research findings is reflected in the variability in PSE’s regulation 
by anti doping agencies and other sporting bodies. The International Olympic 
Committee banned PSE until 2004 when the World Anti-Doping Agency (WADA) 
removed it from the prohibited list. In 2010, after a monitoring program that suggested 
increased use by athletes following the lifting of the ban, it was banned again. 
However, pseudoephedrine is not banned in professional sports that do not follow the 
WADA prohibited list, one example being ice hockey, in which it is used extensively. 
Even one pill a day used as a decongestant can trigger a positive drug test and this 
can lead to unfortunate consequences such as the banning of Swedish National 
Hockey League player Nicklas Backstrom from the gold medal game of the Sochi 2014 
Winter Olympics.  
 
A recent systematic review by Trinh et al. [3] used qualitative analysis to suggest that 
only higher doses of PSE are likely to enhance performance. The authors argued the 
limited studies available were too heterogeneous to perform a quantitative meta-
analysis to supplement their findings. We performed a new review, finding seven 
additional articles not included by Trinh et al. [3]. The inclusion of these articles made 
a quantitative analysis possible, not just in terms of PSE’s potential effect on 
performance, but also on physiological (heart rate [HR]), biochemical (blood glucose 
[GLU], blood lactate [LAC]) and psychological (RPE) markers that could inform on the 
proposed mechanism of action. Our analysis provides quantitative support for the 
qualitative assertion by Trinh et al. [3] that therapeutic doses of PSE do not affect 
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performance. However, we also question their view that supratherapeutic doses of 
PSE induce an ergogenic effect. 
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Main Text 
1. Methods 
This review complies with the Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses (PRISMA) statement [16]. An extensive literature search was carried 
out prior to statistical analyses using a random-effects model. 
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1.1 Search and selection strategy 
Figure 1 outlines the search process. A search of the PubMed database took place in 
October and November, 2015. After the identification of 13 eligible studies, a citation 
track was conducted and three more articles were found. This was combined with a 
search of articles’ references lists, focusing on those which had cited the original 13 
articles identified. This was further supplemented by Google Scholar searches in 
November, 2015 and August 2017. As of February 2018, no new relevant references 
were found using citation searches of the final 16 articles selected. Terms included in 
the search were ‘pseudoephedrine’ in combination with: ‘heart rate’, ‘time trial’, 
‘athletes’, ‘cycling’, ‘running’, ‘exercise’, ‘ergogenic’, ‘sport’ and ‘doping’. These terms 
were searched for in the title and the abstract of studies.  
 
1.2 Study selection criteria 
Only articles investigating the effect of PSE on exercise performance were selected. 
Authors must have provided enough information to derive means and standard 
deviations for performance tests. Studies must have used PSE as the only substance 
in the intervention, and they were excluded if the substance was not specifically being 
investigated for its ergogenic effect [17]. Also excluded were studies investigating the 
effects of PSE on strength and neuromuscular coordination because data were 
incomparable with included articles [10,18]. Studies that investigated other substances 
were included if participants were not administered both substances simultaneously 
[7,12,19]. All studies were randomised placebo-controlled trials and were conducted 
in a double blind crossover fashion. All participants (males and females) were deemed 
to be healthy. Each protocol of the 16 studies included in this meta-analysis required 
the participants to abstain from use of stimulants before the trials and some studies 
had a pre-planned meal. 
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1.3 Data extraction 
To estimate the effect of PSE on performance, data for the following variables were 
extracted from the gathered articles where available: HR, GLU, LAC, time trial (TT) 
performance and RPE. Table 1 shows the characteristics of the sixteen studies 
included in the meta-analysis. Eleven of these measured HR [7,8,11,13–15,19–23], 
five measured GLU [6,7,14,15,23], six measured LAC [7,13–15,19,24], nine measured 
TT [9,14,15,19,21–25], and five measured RPE [8,12,15,22,23]. Where data were 
presented only in figures [7,24], authors were directly contacted for the raw data. If 
these were not available, the figures were enlarged and values were calculated using 
a ruler [26]. 
Table 1. Characteristics of studies included in the meta-analysis 
Authors Title of study 
PSE dose 
(mg) 
Time of 
ingestion 
pre 
exercise 
(min) 
Washo
ut 
period 
(days) 
VO2 max 
(ml/kg/min) 
No. of 
participan
ts 
Sex 
(mean 
age ± 
SD) 
Type of exercise 
Dominant 
energy source 
for exercise 
Parameters measured 
(included in meta-
analysis) 
Subgroup 
for analysis Conclusion of study 
Bright et al. [6] 
“Selected cardiac and metabolic 
responses to pseudoephedrine with 
exercise” 
60 or 120 60 7 / 6 
Male 
(25.5) 
Approx. 12 min multistage treadmill 
running exercise until 85% max. 
HR was reached 
Aerobic blood glucose 
LD, SE, YA, 
LW, SI, RU 
No significant changes in 
cardiovascular or metabolic 
parameters. 
Clemons and 
Crosby [8] 
“Cardiopulmonary and subjective 
effects of a 60mg dose of 
pseudoephedrine on graded 
treadmill exercise” 
60 70 7 58.46 10 
Female 
(20.4 ± 
1.71) 
Seven 3 min continuous running 
exercise stages with speed 
increasing at 19.22 metres/min in 
each stage 
Aerobic HR, RPE  
LD, SE, YA, 
VL, LW, SI, 
RU 
No effect although it may 
augment submaximal 
exercise HR and slow HR 
recovery. 
Gillies et al. [9] 
“Pseudoephedrine is without 
ergogenic effect during prolonged 
exercise” 
120 120 7 / 10 
Male 
(23.3 ± 
2.84) 
Approx. 60 min high-intensity 
exercise (40 km cycling time trial) 
Aerobic TT 
LD, LE, YA, 
LW, LI, CY 
No ergogenic effect during 
prolonged exercise. 
Swain et al. [12] 
“Do pseudoephedrine or 
phenylpropanolamine improve 
maximum oxygen uptake and time to 
exhaustion?” 
1 mg/kg 
or 2 
mg/kg 
(78.62 mg 
or 157.24 
mg) 
60 7 59.52 20 
Male 
(27.1 ± 
3.73) 
10s to achieve 80 rpm in a cycling 
trial with test ending when subjects 
are unable to maintain speed after 
10s  
 Aerobic RPE 
LD, SE, YA, 
VL, LW, SI, 
CY 
No ergogenic effect. 
Gill et al. [13] 
“Muscular and cardiorespiratory 
effects of pseudoephedrine in 
human athletes” 
180 45 7 / 22 
Male 
(21.0 ± 
2.8) 
Maximal (30 s “all-out”) cycle sprint 
(cycling) 
Anaerobic HR, blood lactate 
HD, SE, YA, 
LW, SI, CY 
Improved peak power 
during maximal cycle 
performance. 
Chester et al. [7] 
“Physiological, subjective and 
performance effects of 
pseudoephedrine and 
phenylpropanolamine during 
endurance running exercise” 
60 (6 
doses 
over 36h) 
240 7 65.46 8 
Male 
(29.58 ± 
8.42) 
20 min running followed by a 
5,000-m time trial 
Aerobic HR, blood lactate, blood 
glucose 
HD, LE, OA, 
VH, LW, LI, 
RU 
No ergogenic effect with 
regard to endurance 
running. 
Hodges, et al. 
[11] 
“Effects of pseudoephedrine on 
maximal cycling power and 
submaximal cycling efficiency” 
60 90 3 56.8 11 
Male 
(29.0 ± 
8.6) 
10 min cycling test (at 40% and 
60% of peak power) and 30 s 
maximal cycle test 
Aerobic and 
Anaerobic HR 
LD, SE, OA, 
VL, SW, LI, 
CY 
No effect on anaerobic 
cycling performance or 
aerobic cycling efficiency. 
Hodges, et al. 
[14] 
“Pseudoephedrine enhances 
performance in 1500-m runners” 
2.5 mg/kg 
(170 mg) 
90 7 68.7 7 (1 dropout) 
Male 
(20.1 ± 
1.2) 
1,500-m running exercise Aerobic 
HR, blood lactate, blood 
glucose, TT 
LD, SE, YA, 
VH, LW, LI, 
RU 
Improvement (by 2.1%) in 
1,500-m running 
performance. 
Mouatt [23] 
“The physiological effects of 
pseudoephedrine on endurance 
cycling” 
2.5 mg/kg 
(184 mg) 
90 6 66.1 10 
Male 
(29.7 ± 
7) 
120 min cycling exercise at fixed 
intensity and 30 min self-paced 
time trial 
Aerobic 
HR, blood glucose, TT, 
RPE 
HD, LE, OA, 
VH, SW, LI, 
CY 
Increased heart rate but 
unchanged cycling 
performance during 
endurance cycling. 
Betteridge et al. 
[20] 
“The effect of pseudoephedrine on 
self-paced endurance cycling 
performance” 
2.5 mg/kg 
(187.5 
mg) 
90 6 69 8 
Male 
(29.0 ± 
6) 
150 min cycling exercise at 70% 
VO2 max 
Aerobic HR, TT 
HD, LE, OA, 
VH, SW, LI, 
CY 
No effect on self-paced 
endurance exercise 
performance but may affect 
the cardiac response to 
exercise. 
Pritchard-
Peschek et al. 
[15] 
“Pseudoephedrine ingestion and 
cycling time-trial performance” 
180 60 3.5 56.8 6 
Male 
(33 ± 2) 
Approx. 30 min cycling exercise at 
7kJ/kg BM workload 
Aerobic HR, blood lactate, blood 
glucose, TT, RPE 
HD, LE, OA, 
VL, SW, SI, 
CY 
Significantly improved 
cycling TT performance by 
5.1% compared to placebo. 
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PSE, pseudoephedrine; HR, heart rate; RPE, rate of perceived exertion; TT, time trial; s, second(s); min, minute(s); h, hour; m, metre(s); km, kilometre(s); 
rpm, rotations per minute; VO2max, maximum oxygen uptake; BM, body mass. Grey shading denotes study not included in the systematic review by Trinh 
et al [3]. Subgroup code (see Table 3 for quantitative details): high dose/low dose (HD/LD); long/short exercise duration (LE/SE); older/younger (OA/YA); 
VO2max higher/lower (VH/VL); long washout/short washout (LW/SW); long/short pre-exercise ingestion time (LI/SI); cycling/running (CY/RU). PSE dose given 
as ‘mg/kg’ was converted to ‘mg’ using mean body mass of participants.
Berry and 
Wagner [21] 
“Effects of pseudoephedrine on 800-
m run times of female collegiate 
track athletes” 
2.5 mg/kg 
(144 mg) 
90  7 / 13 (2 dropouts) 
Female 
(19.6 ± 
1.3) 
800-m running exercise Aerobic HR, TT 
LD, SE, YA, 
LW, LI, RU 
No effect on 800-m running 
performance. 
Gradidge et al. 
[22] 
“Effect of a therapeutic dose of 
pseudoephedrine on swimmers’ 
performance” 
90 mg/day 
Performan
ce was 
measured 
after a 4-
day period 
of 
ingestion 
of PSE 
4 / 7 
Male 
and 
Female 
(44 ± 7) 
50-m sprint and 2000-m swimming 
exercise 
Anaerobic and 
Aerobic HR, TT, RPE 
LD, LE, OA, 
SW 
No major effect with regard 
to swimming. 
Pritchard-
Peschek et al. 
[24] 
“Pseudoephedrine and preexercise 
feeding: influence on performance” 
2.8 mg/kg 
(204 mg) 
110 7 64.8 10 
Male 
(30.6 ± 
6.6) 
Approx. 30 min cycling time trial at 
7kJ/kg BM workload 
Aerobic blood lactate, TT 
HD, LE, OA, 
VL, LW, LI, 
CY 
No effect on cycling TT 
performance of approx. 30 
min. 
Pritchard-
Peschek et al. 
[25] 
“The dose-response relationship 
between pseudoephedrine ingestion 
and exercise performance” 
2.3 mg/kg 
or 2.8 
mg/kg) 
(172.7 mg 
or 210.28 
mg) 
85 7 65 10 
Male 
(26.5 ± 
6.2) 
Approx. 30 min cycling time trial at 
7kJ/kg BM workload 
Aerobic TT 
HD, SE, YA, 
VH, LW, LI, 
CY 
No effect on cycling TT 
performance. 
Spence et al. 
[19] 
“A comparison of caffeine versus 
pseudoephedrine on cycling time-
trial performance” 
180 60 2 58.9 10 
Male 
(30 ± 2) 
Approx. 60 min exercise (40-km 
cycling time trial) 
Aerobic HR, blood lactate, TT 
HD, LE, OA, 
VL, SW, SI, 
CY 
No significant improvement 
on cycling TT. 
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1.4 Statistical analysis 
The meta-analysis was carried out using the RevMan [27] software. The inverse-
variance random-effects model for meta-analyses was used as it proportionately 
weights studies based on the magnitude of their standard errors [28] and accounts for 
heterogeneity across trials [29]. Effect sizes are presented as the standardised mean 
difference with 95% confidence intervals and were evaluated with the scale of Hopkins 
et al. [30]: <0.2 = trivial; 0.2-0.59 = small, 0.6-1.19 = moderate, 1.2-1.99 = large, 2.0-
3.99 = very large, ≥4.0 = extremely large. To account for the crossover design of the 
included studies, data for experimental and placebo conditions were analysed in the 
manner of a parallel group trial [28]. This method can result in wider than normal 
confidence intervals and underweighting of studies [28] though the short half-life of 
PSE (≤8 hours [31]), coupled with more extensive washout periods, reduces the 
confounding impact of these factors. Study heterogeneity is represented by the I2 
statistic which is the variation of effects that could be attributed to differences across 
studies rather than to chance. Low, moderate and high heterogeneity correspond to I2 
values of 25%, 50% and 75% respectively [32]. 
2. Results 
The 16 analysed studies included 168 participants. Most (81%) had only male 
participants while two (12.5%) had only female participants. One (6.5%) study included 
both sexes. Mean ages ranged from 18 to 38 years, with only one study [22] allowing 
participants up to 60 years. Participants were either competitive athletes or volunteers 
with an interest in sport. 
 
2.1 Primary effects 
The pooled mean estimates for the effect of PSE on HR, TT, RPE, GLU, LAC are 
shown in Table 2 and Figures 2 to 6. Effects were generally positively or negatively 
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trivial across parameters with the exception of HR which showed a small positive effect 
in favour of PSE ingestion. 
 
Table 2. Effect sizes and descriptors for paramters studied 
 
Parameter HR TT RPE GLU LAC 
Effect size 
(95% 
confidence 
interval) 
0.43 (-0.01, 
0.88) 
-0.17 (-
0.46, 
0.13) 
-0.08 (-0.47, 
0.30) 
-0.19 (-0.66, 
0.27) 
-0.15 (-0.69, 
0.38) 
Effect size 
descriptor 
Small increase Trivial 
decrease 
Trivial 
decrease 
Trivial 
decrease 
Trivial 
decrease 
 
HR, heart rate; TT, time trial; RPE, rate of perceived exertion; GLU, blood 
glucose; LAC, blood lactate. 
 
 
 
Figure 2 Forest plot for effects of PSE on HR with 95% confidence intervals 
 
 
Figure 3 Forest plot for effects of PSE on TT with 95% confidence intervals 
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Figure 4 Forest plot for effects of PSE on RPE with 95% confidence intervals 
 
 
 
Figure 5 Forest plot for effects of PSE on GLU with 95% confidence intervals 
 
 
Figure 6 Forest plot for effects of PSE on LAC with 95% confidence intervals 
 
 
2.2 Effects in subgroups 
Subgrops, chosen by a median split, revealed important trends (Table 3). Effect sizes 
on HR and TT tended to be larger in well-trained (≥65 ml/kg/min) and younger (<28 
years) participants. Effects were also larger for shorter (<25 mins) bouts of exercise 
and when PSE was administered less than 90 minutes prior to performance. For longer 
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duration exercise (≥90 mins), small effects were also apparent for RPE. There was 
evidence of a dose-response for TT and HR with larger doses (>170 mg) resulting in 
small and moderate effect sizes respectively for these variables. 
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Table 3 . Subgroup analysis 
 
    HR TT RPE GLU LAC 
Subgroup 
Median 
split 
Effect 
size 
Groups N 
Effect 
size 
Groups N 
Effect 
size 
Groups N 
Effect 
size 
Groups N 
Effect 
size 
Groups N 
PSE 
Dose 
>170 mg 0.85 6 49 -0.24 6 54 0.00 2 16 -0.08 3 24 -0.09 5 56 
≤170 mg 0.11 5 48 -0.06 4 37 -0.11 3 37 -0.41 2 13 -0.51 1 7 
Exercise 
duration 
≥25 mins 0.38 6 49 -0.08 7 61 0.02 3 23 -0.08 3 24 -0.10 4 34 
<25 mins 0.55 5 48 -0.34 3 30 -0.16 2 30 -0.41 2 13 -0.18 2 29 
Age 
>28 
years 
0.32 7 60 -0.12 6 51 0.02 3 23 -0.08 3 24 -0.10 4 34 
<28 
years 
0.77 4 37 -0.22 4 40 -0.16 2 30 -0.41 2 13 -0.18 2 29 
VO2 max 
≥65 
ml/kg/min 
0.69 4 33 -0.40 4 35 -0.31 1 10 -0.18 3 25 -0.52 2 15 
<65 
ml/kg/min 
0.07 4 37 -0.10 3 26 -0.06 3 36 -0.27 1 6 0.05 3 26 
Washout 
period 
(days) 
≥7 days 0.65 5 45 -0.19 5 50 -0.16 2 30 -0.07 3 21 0.00 4 47 
<7 days 0.31 6 52 -0.14 5 41 0.02 3 23 -0.36 2 16 -0.51 2 16 
Pre-
exercise 
ingestion 
time 
≥90 mins 0.41 6 57 -0.10 6 58 -0.31 1 10 -0.18 3 25 0.03 3 25 
<90 mins 0.54 5 40 -0.34 3 26 -0.06 3 36 -0.21 2 12 -0.30 3 38 
Mode of 
exercise 
Cycling 0.77 6 52 -0.09 6 54 -0.04 3 36 -0.36 2 16 0.00 4 48 
Running 0.18 5 45 -0.16 2 20 -0.36 1 10 -0.07 3 21 -0.52 2 15 
 
PSE, pseudoephedrine; HR, heart rate; RPE, rate of perceived exertion; TT, time trial; GLU, Blood glucose; LAC, Blood lactate; min, minute(s);  VO2max, 
maximum oxygen uptake. 
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3. Discussion  
Our results quantitatively demonstrate that PSE causes a small increase in HR during 
exercise. In terms of the other parameters studied, there were trivial improvements in 
time trial performance, a trivial reduction in RPE and trivial decreases in GLU and LAC 
levels during exercise. It could be argued that these equivocal findings suggest a meta-
analysis would better wait until a larger number of studies have been performed, thus 
leading to a more robust conclusion. However, the intriguing subgroup analyses 
argues against this. Effect sizes tended to be larger in just those athletes of most 
concern to anti-doping agencies (younger and well-trained athletes). They also 
suggest an optimal time and activity to take the drug, indicating PSE is most effectively 
administered less than 90 minutes before a short bout of exercise of less than 25 
minutes. Of particular concern is that our subgroup analysis confirms the qualitative 
review [3] that larger doses (>170 mg) are likely to be the most effective in improving 
performance. However, this was accompanied by a larger effect on increasing HR. A 
recent study looking at neuromuscular performance effects using these more effective 
higher PSE doses (180 mg) noted adverse side effects such as tachycardia and heart 
palpitations 24 hours after exercise [18]. This suggests it will be increasingly difficult to 
get ethical approval to test the most effective doses of PSE, making it important to 
carry out the most complete analysis of the studies that have already been performed.  
 
3.1 Comparison to previous systematic reviews  
The initial search for our systematic review was carried out at approximately the same 
time as that of the recent systematic review by Trinh et al. [3] and subsequent searches 
uncovered no additional studies of interest. However, the studies deemed appropriate 
for detailed analysis were different. Whilst our search confirmed and agreed with the 
many of the studies chosen by Trinh et al. [3], we included some additional 
publications. As our enhanced sample enabled the meta-analysis that Trinh et al, [3] 
 18 
felt not to be justified, we feel it is important to justify the rationale for the additional 
papers chosen. 
 
Both reviews focused on the performance effects of PSE using a randomised-
controlled trial approach. As our study was designed to enable a meta-analysis, it was 
restricted to sports performances that had a time trial component and/or included 
quantitative measures that could inform potential underlying mechanisms (such as 
LAC, GLU, HR and RPE). This biased our search to include only those studies that 
focused on sports events with an aerobic component. This approach ruled out one 
article included by Trinh et al. [3], a study by Chu et al. [10] showing that a moderate 
dose (120 mg) of PSE did not alter muscle action strength or anaerobic power. It also 
ruled out a recent study published after both systematic searches. In 2015 Pallarés et 
al. [18] measured bench press and full squat exercise performance against four 
incremental loads (25%, 50%, 75%, and 90% one repetition maximum). No effects 
were seen except in the highest dose studied (180mg) where PSE seemingly 
increased lower body muscle contraction velocity.  
 
Trinh et al. [3] conducted their analysis on only 10 studies and concluded that the data 
were insufficient and too variable to enable a meta-analysis. We feel that, at least in 
part, this conclusion is based on the combination of a flawed search strategy and an 
overly restrictive view of which articles to select from that search. We found seven 
additional papers omitted by Trinh et al. [3], all of which used randomised placebo 
designs to assess the effect of PSE on aspects of performance. On this basis, these 
studies could, in principle, fit the criteria used by Trinh et al. [3]. These articles are 
highlighted in Table 1 and owing to their importance to our final meta-analysis, it is 
crucial that we justify their inclusion individually (see discussion in Table 4).    
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Table 4  Characteristics of studies included in this meta-analysis that were not 
included in Trinh et al. [3] systematic review 
 
Authors Title of study Rationale for inclusion in the meta-analysis 
Bright et al. (6) 
“Selected cardiac and 
metabolic responses to 
pseudoephedrine with 
exercise” 
This paper studied the cardiac and metabolic responses to pseudoephedrine with 
exercise. As GLU after exercise was measured (a non significant small decrease was 
seen), it was included in our study. The relevant performance measure was ‘time to 
reach 85% of maximum HR’ during submaximal exercise, with no effect being seen. 
The inclusion criteria of Trinh et al. accounted for “any enhancement in sport above 
baseline such as timing, strength, time to fatigue and/or respiratory enhancement”. 
Although it did not fit our time trial criteria, it is at least arguable that time to reach 
85% of maximum HR fits those of Trinh et al. 
 
Clemons and Crosby 
(8) 
“Cardiopulmonary and 
subjective effects of a 60mg 
dose of pseudoephedrine on 
graded treadmill exercise” 
This evaluated the cardiopulmonary and subjective effects of a 60mg dose of PSE on 
graded treadmill running. The RPE and HR data recorded during exercise were 
included in our meta-analysis. However, the time to exhaustion was not, as it was a 
graded exercise test rather than a time trial. Despite this, it would seem that time to 
fatigue on a treadmill would fit well with the Trinh et al. criteria, so it was not clear why 
they did not discuss this research. 
 
Mouatt (23) 
“The physiological effects of 
pseudoephedrine on 
endurance cycling” 
This study looked at the effects of high dose (2.5 mg/kg ≅ 184 mg total) PSE on 
endurance cycling. This comprehensive randomised controlled trial was included in 
our analysis as it measured HR, GLU, RPE and TT duration. A difficult study to find 
owing to it only being published as an MSc. thesis, it is freely and readily available in 
open access form via standard search engines (Google etc.). Nevertheless, as a 
research thesis from a well-recognised university (Massey), supervised by a well-
published author in the sports and exercise science field (Toby Mündel), we feel it is 
appropriate to add to our analysis.  
 
Betteridge et al. (20) 
“The effect of 
pseudoephedrine on self-
paced endurance cycling 
performance” 
This used a randomised controlled study design to measure HR, GLU, LAC, RPE and 
TT duration after a high dose PSE. Heart rate and TT were included in our meta-
analysis, however changes in GLU and LAC values could not be used as they were 
not reported in sufficient detail. The European Journal of Sports Science is the official 
journal of the European College of Sports Science, but was not listed in Medline until 
2013 so the search strategy of Trinh et al. would not have uncovered it as their 
search strategy excluded sports and exercise science databases. Trinh et al.’s criteria 
also did not include citation or reference searches of the final selected papers, which 
might have rectified this omission as the relevant article was commented on in the 
discussion of one of the studies [25] that was cited by Trinh et al.  
 
Gradidge et al. (22) 
“Effect of a therapeutic dose of 
pseudoephedrine on 
swimmers’ performance” 
This paper explored the effect of a low dose of PSE on swim performance (TT, RPE 
and HR data were included in our analysis). This double blind randomised controlled 
trial was published in the South African Journal of Sports Medicine, which is absent 
from the search database used by Trinh et al. [3]. 
 
Pritchard-Peschek (24) 
“Pseudoephedrine and 
preexercise feeding: influence 
on performance” 
An apparent inconsistency occurred in the selection of studies from Pritchard-
Peschek and collaborators between ourselves and Trinh et al [3]. Between 2010 and 
2014 this group published three randomised controlled trials on PSE and exercise 
performance. All included TT data and so were included in our meta-analysis. 
However, Trinh et al., only included the papers published in 2010 [15] and 2014 [25], 
despite the 2013 paper being published in Medicine and Science in Sports and 
Exercise and hence readily accessible by Medline. Their 2013 paper [24] had a 
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similar protocol to those in 2010 and 2014 [25], but with the addition of a pre-
ingestion meal group. However, this additional group could be easily removed for 
consistency with the other two studies and so was included in our analysis.  
Spence et al. (19) 
“A comparison of caffeine 
versus pseudoephedrine on 
cycling time-trial performance” 
This paper was analysed by Trinh et al., but specifically excluded from their analysis. 
It compared caffeine and PSE in cycling time trial performance. Trinh et al. excluded 
the study as they stated it “focuses on differences between effects of caffeine and 
PSE”. However, in their inclusion criteria they note that “studies that looked at other 
substances were included if athletes were not administered both substances 
simultaneously.” This article outlined three experimental arms (caffeine, PSE and 
placebo) in a cross-over study with adequate wash out periods between trials. It is 
true that the authors focus on the differences between caffeine and PSE in their 
discussion, but they give full statistics (means, standard deviations and effect sizes) 
for a comparison between PSE and placebo. In light of this, by their own criteria we 
feel that Trinh et al. should not have excluded this study.  
 
 
Given that Trinh et al. [3] only included ten articles in their final qualitative synthesis, 
the exclusion of seven relevant studies represents a significant fraction of the available 
literature. Crucially, all seven studies excluded showed no effect of PSE on 
performance. This may not be related to a dose effect as three studies [6,8,22] were 
at low (clinically approved) doses and four were at supratherapeutic doses 
[19,20,23,24]. It is possible that excluding such a large fraction of data biased the final 
conclusion of that review, particularly the comment that “qualitative analysis showed 
overall positive results in favour of PSE over placebo for PSE doses ≥180 mg or 2.5 
mg/kg”. Of the ten studies included by Trinh et al. [3], all three high dose studies 
showed an ergogenic effect, and all seven lower dose studies showed PSE to be 
ineffective, making their conclusion reasonable. However, adding the seven omitted 
studies would significantly weaken this argument as only 3 out of 7 high dose studies 
demonstrate a positive effect of PSE. Therefore, although there is clearly an increase 
in HR during exercise due to PSE, we are more equivocal than Trinh et al. [3] about 
the drug’s positive ergogenic effects, even at high doses. Including these new articles 
does, however, strongly favour the conclusion that when taken at clinically 
recommended doses, PSE has only a very minor effect on HR and no ergogenic effect 
in terms of performance.  
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3.2 Relevance for putative mechanism of any performance benefit  
Our analysis suggests that only at high doses does PSE have the potential to enhance 
sports performance. It also sheds some light on to the possible mechanism that could 
be operating. A previous meta-analysis demonstrated that, at rest, PSE caused a 
statistically significant small increase in systolic blood pressure (1 mm Hg) and HR (3 
beats/min), although diastolic blood pressure did not change. We found 11 studies 
reporting HR changes following PSE ingestion during exercise. Our data showed that 
this mean HR increase is maintained during exercise with the largest increase being 
13 beats/min [20]. The subgroup analyses showed that the biggest effect sizes were 
seen at high doses and in athletes with high maximal oxygen uptake (VO2max). Three 
individual studies showed a performance effect [13–15]. Gill et al. [13] showed that HR 
increased significantly from 166 to 175 beats/min, and Hodges et al. [14] demonstrated 
a non-significant increase from 185 to 190 beats/min. Similarly, Pritchard-Peschek et 
al. [15] also reported a non-significant increase was from 176 to 180 beats/min. Given 
that studies that showed no performance increase showed at least as large and as 
significant HR increases during exercise, it seems unlikely that – in and of itself – 
changes in HR underpin any performance enhancement. 
 
In relation to RPE, GLU and LAC levels in exercise, a lack of data is more challenging 
to overcome with only between five and seven studies reporting sufficient information. 
We observed a small, trivial decrease in all of these parameters. However, it is worth 
exploring the individual studies, as the statistical power of pairing individuals in a 
crossover study is lost during a meta-analysis.  
 
For RPE, none of the five studies included showed meaningful differences between 
PSE and placebo [8,12,15,22,23]. An additional study did not report values, but did 
state that there were no significant differences [7]. Glucose levels were not significantly 
different in four of the five studies included in the meta-analysis [6,7,14,23]. An 
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additional study, not part of the analysis as it reported no values, again stated a lack 
of any PSE effect on GLU [25]. However, one study did report increased GLU levels 
post exercise following PSE treatment [15]. This was one of the few studies that also 
showed a performance effect (decreased time in cycling TT). Interestingly in this case, 
it was the pre exercise GLU level that correlated with the increased performance in the 
cycling time trial. Lactate levels did not significantly change in five of the seven studies 
included in the meta-analysis [7,13–15,23]. However, they did significantly decrease 
in two studies [19,24]. In one study LAC levels were not reported, the authors 
nonetheless stating there was no significant change [25].   
 
Given that only three of the sixteen studies included in our analysis showed a 
performance benefit, it is worth exploring in detail, which secondary parameters 
changed in these studies to see if this can inform mechanism. Gill et al. [13] measured 
an increase in maximum torque in an isometric knee extension and an improvement 
in peak power during maximal cycle performance in 22 healthy male volunteers. In 
terms of lung function, small, but significant, increases were seen in forced vital 
capacity (FVC) and forced expired volume in one second (FEV) following ingestion of 
PSE. These are consistent with the well-characterised role of PSE in stimulating the 
sympathetic nervous system and acting as a bronchodilator [33]. This is unlikely to 
explain the effect on peak power observed here, nor is a small increase in FVC and 
FEV likely to improve sports performance in endurance events given the lack of 
consistent ergogenic effect of drugs that are far more effective in increasing lung 
function such as salbutamol [34].    
 
Hodges et al. [14] found that PSE significantly decreased time to completion of a 
1500m time trial in 7 healthy male subjects. However, no other measured parameters 
(HR, LAC, GLU, arterial O2 partial pressure, arterial carbon dioxide partial pressure 
and arterial oxygen saturation) were significantly altered.  
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Pritchard-Peschek et al. [15] reported a significant improvement in a cycling TT 
performance following PSE in 6 trained male cyclists and triathletes. As previously 
noted, this study reported increased post exercise GLU levels following PSE treatment. 
No significant PSE effect was found on LAC, blood pH, substrate oxidation, RPE or 
HR. PSE did significantly increase plasma norepinephrine concentrations, an 
expected outcome for a drug that has indirect agonist activity on cardiac  receptors 
and peripheral 1 receptors, through release of norepinephrine from the cytoplasmic 
pool [14]. However, the validity of any ergogenic effects of this increased  receptor 
activity is undermined by the two subsequent similar studies from this group, which 
used larger sample sizes (n=10) and showed no performance benefit despite an 
increase in plasma norepinephrine [24,25].  
 
Readily available drugs used as decongestants that are not banned by WADA such as 
phenylephrine act directly on peripheral  receptors and have limited ability to cross 
the blood brain barrier and/or act as a central stimulant [2]. PSE is more lipid soluble 
and is therefore more accessible to the central nervous system. Consequently, it can, 
in principle, act as both a peripheral or central stimulant. However, the biochemical, 
physiological and psychological data in our systematic review and meta-analysis fail 
to give a consistent explanation to underpin a possible ergogenic mechanism. Heart 
rate did increase, however, in most studies there was no accompanying performance 
benefit; indeed in some studies which showed a performance benefit, there is no 
significant heart rate change. A few studies show plasma metabolite changes 
(GLU/LAC) that might suggest improved substrate or oxygen utilization. However, 
other studies show no metabolite changes even when there is a performance benefit. 
Unlike other WADA banned stimulants such as amphetamines [35], perception of effort 
(RPE) is completely unchanged by PSE at low or high doses, irrespective of any 
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performance benefit.  
 
 
3.3 Rationale for WADA listing pseudoephedrine as a prohibited doping 
substance 
The WADA Prohibited List may include any substance that satisfies any two of the 
following three criteria: (i) it has the potential to enhance or enhances sport 
performance; (ii) it represents an actual or potential health risk to the athlete; (iii) it 
violates the spirit of sport. Apparently, PSE fulfilled these criteria and was banned until 
2004, did not fulfill them between 2004 and 2010 (when it was removed from the 
banned list) and then fulfilled them again after 2010 (when it returned to the banned 
list). Currently PSE is only banned in competition. A doping offence is committed if an 
athlete has a urine PSE concentration of greater than 150 g/ml. Even given the 
biological variability of single point measurements, this level is high enough that it 
should not be possible to produce a positive urine test if an athlete discontinues a 
therapeutic dose of PSE more than 24 hours before competition. However, it is 
possible, though not guaranteed, to exceed these levels within 24 hours of taking PSE 
at the normal therapeutic dose [9], and it is impossible not to exceed them when on a 
supratherapeutic dose [24]. 
 
WADA monitored PSE use in doping samples when it was not banned from 2004-
2009. WADA’s case for reintroducing the PSE ban in 2010 was made in a Q and A 
statement published as part of the 2010 prohibited list [36]:  
 
“Results of the Monitoring Program over the past five years have shown a sustained 
increase in samples containing pseudoephedrine. The program indicated clear abuse 
of this substance with high concentrations in a number of sports and regions. In 
addition, available literature shows scientific evidence of the performance-enhancing 
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effects of pseudoephedrine beyond certain doses.” 
 
Some increase in PSE use would be expected when the ban was lifted given that the 
best drug to treat nasal decongestion in competition was now freely available to 
athletes without the threat of sanction. Presumably, the geographic and sport-specific 
nature of the increase argued against this more benign interpretation. An additional 
concern, not specifically noted by WADA, but stated by some anti-doping researchers, 
is that one of PSE’s minor metabolites, norpseudoephedrine (cathine), was on the 
banned list during this period. Athletes could therefore claim a failed cathine doping 
result was a consequence of taking the now permitted PSE. PSE use would, therefore, 
mask cathine abuse [37].  
 
However, our systematic review does question WADA’s statement that “available 
literature shows scientific evidence of the performance-enhancing effects of 
pseudoephedrine beyond certain doses.” A research article would need to have been 
published between 2004 and 2009 to inform this change of policy. In this period our 
search uncovered three studies reporting no performance effect [7,14,23] and only one 
coming to the contrary view [14]. That study was published in 2006 and is the only 
paper WADA cite in the 2004-2009 period showing a performance benefit in 
justification of their decision [38]. It showed a performance benefit based on only six 
UK college 1500m runners, the fastest running over 4:15 min for the distance. The 
International Association of Athletics Federations (IAAF) qualifying standard for this 
event in the 2016 Olympics was 3:36 min, making this subject group far from elite. 
Given that PSE is not banned out of competition, a WADA approved study in elite 
athletes would be beneficial to support the current policy. 
 
Given the difficulty of taking measurements in elite athletes, it is possible that WADA 
treat the systematic abuse of a drug by elite athletes as partial evidence for its efficacy 
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in that subject group. The use of a higher than necessary dose of a medicine (or even 
the use at all of a medicine where there is no clinical need) is also considered to be 
against the ”spirit of sport”. A similar rationale was presumably used for the more 
infamous 2016 banning of the cardiac drug meldonium once the extremely widespread 
use of it amongst Eastern European athletes became known [39], despite the poor 
evidence base for its performance enhancing effect. In the case of PSE there is the 
added concern, that in some countries, to get access to the higher doses, athletes 
need to circumvent government regulations designed to combat the production of 
illegal recreational drugs [2]. 
 
Conclusion 
In contrast to a previous systematic review [3], our analysis has shown that any 
performance benefit of PSE is marginal at best, and certainly less than the well-
characterised permitted stimulant caffeine [40]. However, a small performance benefit 
at high doses in elite athletes still cannot be completely ruled out at present. 
 
Abbreviations 
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Figure legend 
Figure 1. Flowchart showing the search process 
 
Figure 2. Forest plot for effects of PSE on HR with 95% confidence intervals 
HR: Heart rate, PSE, pseudoephedrine; PLA, placebo; SD, standard deviation; Std., 
standardized; IV, instrumental variables; CI, confidence interval. Positive effect sizes 
represent an increase in HR due to PSE 
 
Figure 3. Forest plot for effects of PSE on TT with 95% confidence intervals 
PSE, pseudoephedrine; PLA, placebo; SD, standard deviation; Std., standardized; 
IV, instrumental variables; CI, confidence interval. Negative effect sizes represent a 
shorter TT performance due to PSE 
 
Figure 4. Forest plot for effects of PSE on RPE with 95% confidence intervals 
RPE: Rating of perceived exertionPSE, pseudoephedrine; PLA, placebo; SD, standard 
deviation; Std., standardized; IV, instrumental variables; CI, confidence interval. 
Positive effect sizes represent an increased RPE due to PSE. 
 
Figure 5. Forest plot for effects of PSE on GLU with 95% confidence intervals 
GLU: Blood glucose; PSE, pseudoephedrine; PLA, placebo; SD, standard deviation; 
Std., standardized; IV, instrumental variables; CI, confidence interval. Positive effect 
sizes represent an increase in GLU due to PSE  
 
 
Figure 6. Forest plot for effects of PSE on LAC with 95% confidence intervals 
LAC: Blood lactate; PSE, pseudoephedrine; PLA, placebo; SD, standard deviation; 
Std., standardized; IV, instrumental variables; CI, confidence interval. Positive effect 
sizes represent an increase in LAC due to PSE. 
